{"pmid":32345619,"title":"Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/Covid-19 pandemic.","text":["Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/Covid-19 pandemic.","Ann Rheum Dis","Schulze-Koops, Hendrik","Specker, Christof","Iking-Konert, Christof","Holle, Julia","Moosig, Frank","Krueger, Klaus","32345619"],"journal":"Ann Rheum Dis","authors":["Schulze-Koops, Hendrik","Specker, Christof","Iking-Konert, Christof","Holle, Julia","Moosig, Frank","Krueger, Klaus"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32345619","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1136/annrheumdis-2020-217628","keywords":["autoimmunity","biological therapy","inflammation"],"topics":["Prevention"],"weight":1,"_version_":1665441658236305409,"score":8.599203,"similar":[{"pmid":32299795,"title":"Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India.","text":["Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India.","Ann Rheum Dis","Gupta, Latika","Misra, Durga Prasanna","Agarwal, Vishwesh","Balan, Suma","Agarwal, Vikas","32299795"],"journal":"Ann Rheum Dis","authors":["Gupta, Latika","Misra, Durga Prasanna","Agarwal, Vishwesh","Balan, Suma","Agarwal, Vikas"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32299795","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1136/annrheumdis-2020-217509","keywords":["antirheumatic agents","autoimmune diseases","biological therapy","communicable diseases, imported","glucocorticoids"],"locations":["India"],"countries":["India"],"countries_codes":["IND|India"],"topics":["Prevention"],"weight":1,"_version_":1665420747473944576,"score":140.95897},{"pmid":32321723,"title":"What is the true incidence of COVID-19 in patients with rheumatic diseases?","text":["What is the true incidence of COVID-19 in patients with rheumatic diseases?","Ann Rheum Dis","Favalli, Ennio Giulio","Ingegnoli, Francesca","Cimaz, Rolando","Caporali, Roberto","32321723"],"journal":"Ann Rheum Dis","authors":["Favalli, Ennio Giulio","Ingegnoli, Francesca","Cimaz, Rolando","Caporali, Roberto"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321723","week":"202017|Apr 20 - Apr 26","doi":"10.1136/annrheumdis-2020-217615","keywords":["arthritis","biological therapy","hydroxychloroquine"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664895932732276739,"score":102.014786},{"pmid":32340978,"title":"The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.","text":["The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.","Ann Rheum Dis","Monti, Sara","Montecucco, Carlomaurizio","32340978"],"journal":"Ann Rheum Dis","authors":["Monti, Sara","Montecucco, Carlomaurizio"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32340978","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1136/annrheumdis-2020-217545","keywords":["arthritis, rheumatoid","immune system diseases","inflammation"],"locations":["India"],"countries":["India"],"countries_codes":["IND|India"],"weight":0,"_version_":1665351883932303361,"score":93.696945},{"pmid":32317220,"title":"The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.","text":["The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.","The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has posed the world at a pandemic risk. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome. Several efforts are currently made to find a treatment for COVID-19 patients. So far, several anti-viral and immunosuppressive or immunomodulating drugs have demonstrated some efficacy on COVID-19 both in vitro and in animal models as well as in cases series. In COVID-19 patients a pro-inflammatory status with high levels of interleukin (IL)-1B, IL-1 receptor (R)A and tumor necrosis factor (TNF)-alpha has been demonstrated. Moreover, high levels of IL-6 and TNF-alpha have been observed in patients requiring intensive-care-unit hospitalization. This provided rationale for the use of anti-rheumatic drugs as potential treatments for this severe viral infection. Other agents, such as hydroxychloroquine and chloroquine might have a direct anti-viral effect. The anti-viral aspect of immunosuppressants towards a variety of viruses has been known since long time and it is herein discussed in the view of searching for a potential treatment for SARS-CoV-2 infection.","J Autoimmun","Perricone, Carlo","Triggianese, Paola","Bartoloni, Elena","Cafaro, Giacomo","Bonifacio, Angelo F","Bursi, Roberto","Perricone, Roberto","Gerli, Roberto","32317220"],"abstract":["The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has posed the world at a pandemic risk. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome. Several efforts are currently made to find a treatment for COVID-19 patients. So far, several anti-viral and immunosuppressive or immunomodulating drugs have demonstrated some efficacy on COVID-19 both in vitro and in animal models as well as in cases series. In COVID-19 patients a pro-inflammatory status with high levels of interleukin (IL)-1B, IL-1 receptor (R)A and tumor necrosis factor (TNF)-alpha has been demonstrated. Moreover, high levels of IL-6 and TNF-alpha have been observed in patients requiring intensive-care-unit hospitalization. This provided rationale for the use of anti-rheumatic drugs as potential treatments for this severe viral infection. Other agents, such as hydroxychloroquine and chloroquine might have a direct anti-viral effect. The anti-viral aspect of immunosuppressants towards a variety of viruses has been known since long time and it is herein discussed in the view of searching for a potential treatment for SARS-CoV-2 infection."],"journal":"J Autoimmun","authors":["Perricone, Carlo","Triggianese, Paola","Bartoloni, Elena","Cafaro, Giacomo","Bonifacio, Angelo F","Bursi, Roberto","Perricone, Roberto","Gerli, Roberto"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317220","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jaut.2020.102468","keywords":["autoimmunity","biologics","covid-19","coronavirus","dmards","il-6","immunosuppressant. il-1","infection","rheumatic","sars-cov-2","tdmards"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Chloroquine","Hydroxychloroquine"],"_version_":1664815087679963136,"score":92.9634},{"pmid":32321633,"title":"Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases.","text":["Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases.","Joint Bone Spine","Richez, Christophe","Lazaro, Estibaliz","Lemoine, Mael","Truchetet, Marie-Elise","Schaeverbeke, Thierry","32321633"],"journal":"Joint Bone Spine","authors":["Richez, Christophe","Lazaro, Estibaliz","Lemoine, Mael","Truchetet, Marie-Elise","Schaeverbeke, Thierry"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321633","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jbspin.2020.03.010","keywords":["covid-19","health system","inflammatory rheumatic diseases","treatment"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664895932754296832,"score":84.87127}]}